236 related articles for article (PubMed ID: 37149563)
1. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
[TBL] [Abstract][Full Text] [Related]
2. High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.
Han MH; Min KW; Noh YK; Kim JM; Cheong JH; Ryu JI; Won YD; Koh SH; Myung JK; Park JY; Kwon MJ
Cancer Immunol Immunother; 2022 Dec; 71(12):3013-3027. PubMed ID: 35599254
[TBL] [Abstract][Full Text] [Related]
3. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
4. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
6. MiR-92b inhibitor promoted glioma cell apoptosis via targeting DKK3 and blocking the Wnt/beta-catenin signaling pathway.
Li Q; Shen K; Zhao Y; Ma C; Liu J; Ma J
J Transl Med; 2013 Dec; 11():302. PubMed ID: 24325785
[TBL] [Abstract][Full Text] [Related]
7. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
Cho SY; Kim S; Kim G; Singh P; Kim DW
Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Proliferation by Knockdown of Transmembrane (TMEM) 168 in Glioblastoma Cells via Suppression of Wnt/β-Catenin Pathway.
Xu J; Su Z; Ding Q; Shen L; Nie X; Pan X; Yan A; Yan R; Zhou Y; Li L; Lu B
Oncol Res; 2019 Jul; 27(7):819-826. PubMed ID: 30940290
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
12. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
13. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of the circadian clock network correlates with tumour progression in gliomas.
Petkovic M; Yalçin M; Heese O; Relógio A
BMC Med Genomics; 2023 Jul; 16(1):154. PubMed ID: 37400829
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive analysis of the angiogenesis-related genes in glioblastoma multiforme vs. brain lower grade glioma.
Biterge-Sut B
Arq Neuropsiquiatr; 2020 Jan; 78(1):34-38. PubMed ID: 32074192
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of histone acetylation-related genes in glioblastoma and lower-grade gliomas: Insights into drug sensitivity, molecular subtypes, immune infiltration, and prognosis.
Qin J; Fu J; Chen X
J Gene Med; 2024 Mar; 26(3):e3678. PubMed ID: 38500293
[TBL] [Abstract][Full Text] [Related]
17. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
18. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
19. Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas.
Karunasena E; McIver LJ; Rood BR; Wu X; Zhu H; Bavarva JH; Garner HR
Oncotarget; 2014 Aug; 5(15):6003-14. PubMed ID: 25153720
[TBL] [Abstract][Full Text] [Related]
20. MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
